American Heart Association (AHA) 2011 Scientific Sessions

Top News From AHA 2011: Slideshow
Among the AHA 2011 highlights: AIM-HIGH was stopped early due to increase in ischemic stroke in the niacin group vs placebo, and SATURN results showed that high-dose statin therapy resulted in significant regression of coronary atherosclerosis.

• AHA Further Results Show Ethyl-EPA Reduces Atherogenic Particles
  Heartwire from Medscape, November 28, 2011
• AHA More Questions About Who Is at Risk for Coronary Disease
  Heartwire from Medscape, November 28, 2011
• AHA Mipomersen Shows Large LDL Reduction, Side Effects an Issue
  Heartwire from Medscape, November 28, 2011
• AHA Cardiac Stem Cells Improve LV Function in Cardiomyopathy
  Heartwire from Medscape, November 23, 2011
• AHA Increased Inflammation in South Asians After CABG Surgery
  Heartwire from Medscape, November 23, 2011
• AHA OMNI Support for Tighter Postshock Driving Restrictions
  Heartwire from Medscape, November 23, 2011
• AHA Hypertension and Infection Underlies Heart Disease in Africa
  Heartwire from Medscape, November 22, 2011
• AHA Low Vitamin C Portends Worse Heart-Failure Outcomes
  Heartwire from Medscape, November 22, 2011
• AHA Amgen Widens Focus on PCSK9 Cholesterol Drugs
  Reuters Health Information, November 21, 2011
• AHA Abbott Bioabsorbable Stent Helps Arteries Stay Open
  Reuters Health Information, November 21, 2011
• AHA Vitamin D May Not Have Cardioprotective Benefits
  Heartwire from Medscape, November 18, 2011
• AHA 'Nuisance' Bleeds Don't Up CV Events in Non-ST-ACS
  Heartwire from Medscape, November 18, 2011
• AHA Colchicine Halves Postop AF in COPPS Substudy
  Heartwire from Medscape, November 16, 2011
• AHA CLEVER! Exercise Better Than Stenting in Proximal PAD
  Heartwire from Medscape, November 16, 2011
• AHA Early Surgery vs Drugs in Endocarditis Treatments
  Heartwire from Medscape, November 16, 2011
• AHA Clopidogrel 225 mg for Patients With CYP2C19*2 Allele?
  Heartwire from Medscape, November 16, 2011
• AHA CAC Doesn't Immediately Reverse When Risk Factors Improve
  Heartwire from Medscape, November 15, 2011
• AHA Cautious Optimism Welcomes New CETP Inhibitor, Evacetrapib
  Heartwire from Medscape, November 15, 2011
• AHA AIM-HIGH Fallout: Experts Disagree Over Niacin's Niche
  Heartwire from Medscape, November 15, 2011
• AHA 'Enhanced' Counseling May Help Some Obese Patients
  Heartwire from Medscape, November 15, 2011
• AHA Abuse Early in Life Linked to Cardiovascular Risk
  Medscape Medical News, November 15, 2011
• AHA Phone, Internet Intervention Achieves, Maintains Weight Loss
  Heartwire from Medscape, November 15, 2011
• AHA AIM-HIGH: Results Raise Controversy Over Early Stopping
  Heartwire from Medscape, November 15, 2011
• AHA Rosuvastatin and Atorvastatin Equally Regress Atherosclerosis
  Heartwire from Medscape, November 15, 2011
• AHA Elective PCI Doesn't Require Surgical Backup: C-PORT E
  Heartwire from Medscape, November 15, 2011
• AHA Customized Informed Consent Improves Communication
  Heartwire from Medscape, November 15, 2011
• AHA AHA Gets Guideline Updates, Not Answers
  Heartwire from Medscape, November 14, 2011
• AHA Surgical Ablation vs Catheter Ablation in Drug-Refractory AF
  Heartwire from Medscape, November 14, 2011
• AHA Dronedarone a Hazard in High Risk Patients With Permanent AF
  Heartwire from Medscape, November 14, 2011
• AHA Cutting Copays for Post-MI Drugs Helps Outcomes
  Heartwire from Medscape, November 14, 2011
• AHA New-Onset AF in Sepsis Increases Stroke, Death
  Medscape Medical News, November 14, 2011
• AHA Panel Recommends Universal Cholesterol Screening for Kids
  Heartwire from Medscape, November 13, 2011
• AHA Athletic Directors and Doctors Want Standard SCD Screening
  Heartwire from Medscape, November 13, 2011
• AHA 'Bridging' Anticoagulation May Not Be Necessary
  Heartwire from Medscape, November 13, 2011
• AHA No Benefit of IC Over IV Abciximab: AIDA STEMI
  Heartwire from Medscape, November 13, 2011
• AHA Low-Dose Rivaroxaban Looks Good in ACS: ATLAS ACS 2
  Heartwire from Medscape, November 13, 2011
• AHA Bivalirudin Preferable to Abciximab/Heparin in NSTEMI
  Heartwire from Medscape, November 13, 2011
• AHA Vorapaxar Stumbles in ACS, Ups Bleeding Risk: TRACER
  Heartwire from Medscape, November 13, 2011
• AHA Negative Data for Apixaban in Extended VTE Prevention
  Heartwire from Medscape, November 13, 2011
• AHA ACS at AHA: Experts Speculate on Vorapaxar and Rivaroxaban
  Heartwire from Medscape, November 8, 2011
• AHA What's Going to Be Hot at AHA 2011
  Heartwire from Medscape, November 8, 2011